[go: up one dir, main page]

MX2015011700A - Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion. - Google Patents

Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion.

Info

Publication number
MX2015011700A
MX2015011700A MX2015011700A MX2015011700A MX2015011700A MX 2015011700 A MX2015011700 A MX 2015011700A MX 2015011700 A MX2015011700 A MX 2015011700A MX 2015011700 A MX2015011700 A MX 2015011700A MX 2015011700 A MX2015011700 A MX 2015011700A
Authority
MX
Mexico
Prior art keywords
dsm
htf
suppress inflammation
epm
inflammatory
Prior art date
Application number
MX2015011700A
Other languages
English (en)
Inventor
Hermanus Josef Martinus Harmsen
Muhammad Tanweer Khan
Jeremy Wells
Oriana Rossi
Harry James Flint
Sylvia Helen Duncan
Original Assignee
Univ Groningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Groningen filed Critical Univ Groningen
Publication of MX2015011700A publication Critical patent/MX2015011700A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a la medicina, en particular a la inmunología y a la gastroenterología. Específicamente, se refiere a las bacterias probióticas y extractos de las mismas para uso terapéutico para el tratamiento de trastornos inflamatorios como la enfermedad inflamatoria intestinal. Se proporciona una composición que comprende como ingrediente activo la cepa Faecalibacterium prausnitzii HTF-F (DSM 26943) o un extracto de la misma que comprende la matriz polimérica extracelular (EPM, por sus siglas en inglés), y un portador, diluyente o excipiente aceptable. También se proporciona una composición antinflamatoria que comprende la EPM extraída de la cepa F. prausnitzii HTF-F, y un método para la preparación de la misma.
MX2015011700A 2013-03-05 2014-03-05 Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion. MX2015011700A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13157830 2013-03-05
US201361778458P 2013-03-13 2013-03-13
PCT/NL2014/050131 WO2014137211A1 (en) 2013-03-05 2014-03-05 Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation.

Publications (1)

Publication Number Publication Date
MX2015011700A true MX2015011700A (es) 2016-07-20

Family

ID=47827008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011700A MX2015011700A (es) 2013-03-05 2014-03-05 Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion.

Country Status (11)

Country Link
US (1) US20160000838A1 (es)
EP (1) EP2988761A1 (es)
JP (1) JP2016511272A (es)
KR (1) KR20150134356A (es)
CN (1) CN105228635A (es)
AU (1) AU2014226633A1 (es)
BR (1) BR112015020819A2 (es)
HK (1) HK1214954A1 (es)
MX (1) MX2015011700A (es)
RU (1) RU2015137415A (es)
WO (1) WO2014137211A1 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548761B2 (en) * 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
ITMI20131467A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
ES2661684T3 (es) * 2014-03-03 2018-04-03 Fundacio Institut D'investigació Biomèdica De Girona Dr. Josep Trueta Método para diagnosticar cáncer colorrectal a partir de una muestra de heces humanas mediante PCR cuantitativa
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
CN113730442A (zh) 2014-10-31 2021-12-03 潘德勒姆治疗公司 与病症的微生物治疗和诊断有关的方法和组合物
ES2779409T3 (es) * 2014-11-13 2020-08-17 Institut National De Rech Pour L'agriculture L'alimentation Et L'environnement Cepas de Faecalibacterium prausnitzii para tratar y prevenir el dolor gastrointestinal
EP3193901B1 (en) 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
LT3065748T (lt) 2014-12-23 2018-03-12 4D Pharma Research Limited Bacteroides thetaiotaomicron padermė ir jos panaudojimas uždegimo sumažinimui
WO2016126831A1 (en) 2015-02-03 2016-08-11 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating arthritis
US20180050070A1 (en) * 2015-03-12 2018-02-22 The University Of British Columbia Bacterial compositions and methods of use thereof
WO2016183535A1 (en) 2015-05-14 2016-11-17 University Of Puerto Rico Methods for restoring microbiota of newborns
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SG10201912323VA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
PL3307288T3 (pl) 2015-06-15 2019-12-31 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
SMT202200174T1 (it) 2015-06-15 2022-05-12 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
JP6529835B2 (ja) * 2015-06-23 2019-06-12 株式会社フィス 樹状細胞活性化剤
EP3130680A1 (en) * 2015-08-11 2017-02-15 Universitat de Girona Method for the detection, follow up and/or classification of intestinal diseases
GB201519088D0 (en) * 2015-10-28 2015-12-09 Metabogen Ab The use of bacteria formulations
GB201519087D0 (en) * 2015-10-28 2015-12-09 Metabogen Ab Method for adaption
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3394294B1 (en) 2015-12-23 2020-04-22 Compagnie Gervais Danone Compositions for increasing or maintaining faecalibacterium prausnitzii populations
WO2017117142A1 (en) 2015-12-28 2017-07-06 New York University Device and method of restoring microbiota of newborns
FR3046934B1 (fr) * 2016-01-25 2018-01-26 Institut National De La Recherche Agronomique (Inra) Souche de faecalibacterium prausnitzii cncm i-4573 pour le traitement et la prevention d'une inflammation gastro-intestinale
JP7016112B2 (ja) 2016-02-04 2022-02-04 ユニベルシテイト ゲント ヒトおよび動物の健康ための微生物コミュニティーの使用
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3520801A1 (en) 2016-03-04 2019-08-07 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
WO2017210428A1 (en) * 2016-06-01 2017-12-07 Crestovo Llc Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
CN109874329B (zh) * 2016-08-12 2023-08-29 深圳华大生命科学研究院 一种产丁酸栖粪杆菌及其培养方法和应用
EP3511406A4 (en) * 2016-09-06 2020-04-01 BGI Shenzhen FAECALIBACTERIUM LONGUM AND APPLICATION THEREOF
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
EP3388069B1 (en) * 2017-04-12 2019-05-01 ETH Zurich Consortia of living bacteria useful for treatment of microbiome dysbiosis
CA3060226A1 (en) * 2017-04-17 2018-10-25 Baylor College Of Medicine Commensal bacteria as novel treatment for dry eye and sjogren syndrome
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
MA49425A (fr) 2017-06-14 2020-04-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA49373B1 (fr) 2017-06-14 2021-02-26 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP7016085B2 (ja) * 2017-06-16 2022-02-21 ビオフェルミン製薬株式会社 脂肪関連疾患及び／又は炎症の予防又は治療剤
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
CN113730443B (zh) * 2017-09-11 2022-10-04 广州知易生物科技有限公司 脆弱拟杆菌及其提取物在制备防治肠易激综合征的药物中的应用
WO2019139943A1 (en) * 2018-01-09 2019-07-18 The Cleveland Clinic Foundation Treatment and prevention of pathogenic bacterial overgrowth using butyrate-producing bacteria
WO2019139360A1 (ko) * 2018-01-12 2019-07-18 주식회사 엠디헬스케어 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도
KR102282490B1 (ko) 2018-01-12 2021-07-28 주식회사 엠디헬스케어 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도
AU2019306649A1 (en) 2018-07-19 2021-02-04 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
EP3866821B1 (en) * 2018-10-15 2024-02-28 PharmaBiome AG Consortia of living bacteria useful for treatment of colorectal cancer
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
KR102169795B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도
KR102169794B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도
EP4188110A4 (en) * 2020-07-30 2024-08-14 Bactana Corp. METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES
WO2022035269A1 (ko) * 2020-08-14 2022-02-17 주식회사 고바이오랩 피칼리박테리움 프라우스니치이 균주 및 그 용도
KR102185828B1 (ko) * 2020-08-26 2020-12-03 주식회사 엔테로바이옴 피칼리박테리움 프로스니치 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물
JP7570506B2 (ja) * 2020-09-28 2024-10-21 シージェイ バイオサイエンス， インク． 微生物を含む炎症性疾患の診断または治療用組成物
CN117119907A (zh) * 2021-05-06 2023-11-24 雀巢产品有限公司 使用肌醇、赤藓糖醇或山梨糖醇中的至少一种来增强普拉梭菌生长的组合物和方法
CN113797232B (zh) * 2021-10-28 2023-05-26 南昌大学 具有缓解胰岛素抵抗功能的组合物及其应用
CN115074277B (zh) * 2022-06-24 2023-09-26 无锡特殊食品与营养健康研究院有限公司 一株可缓解肥胖的普拉梭菌及其应用
CN118955659A (zh) * 2024-05-31 2024-11-15 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 一种普拉梭菌微生物抗炎分子及其筛选方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2786847C (en) 2010-01-14 2017-08-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (ibd) and irritable bowel syndrome (ibs)
NL2004201C2 (en) * 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
WO2012142605A1 (en) * 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent

Also Published As

Publication number Publication date
AU2014226633A1 (en) 2015-09-03
HK1214954A1 (zh) 2016-08-12
JP2016511272A (ja) 2016-04-14
RU2015137415A (ru) 2017-04-10
EP2988761A1 (en) 2016-03-02
KR20150134356A (ko) 2015-12-01
BR112015020819A2 (pt) 2017-07-18
US20160000838A1 (en) 2016-01-07
WO2014137211A1 (en) 2014-09-12
CN105228635A (zh) 2016-01-06

Similar Documents

Publication Publication Date Title
MX2015011700A (es) Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion.
MX2022005323A (es) Novedosos lactobacillus que tienen diversas funciones, y uso de los mismos.
MX395076B (es) COMPOSICIÓN A BASE DE UN EXTRACTO DE BIOACTIVO DE L. fermentum PARA USARSE EN EL TRATAMIENTO DE CONDICIONES DERMATOLOGICAS HUMANAS.
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX2015009991A (es) Composiciones y metodos.
MX354047B (es) Cepas/celulas de lactobacillus secadas por aspersion, y el uso de las mismas contra helicobacter pylori.
PH12014502243A1 (en) Novel bacillus subtilis
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MX2016014305A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
TW201613880A (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
MY201921A (en) Agent for preventing or treating fat-associated diseases and/or inflammation
WO2014066053A3 (en) Method of prevention and treatment of clostridium difficile infection
MX383749B (es) Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas
WO2017147130A3 (en) Direct fed microbial for prevention of shrimp disease
PH12012501389A1 (en) Hedgehog inhibitors
PH12017500637A1 (en) Inhibitors of lysine gingipain
MY186323A (en) Lactobacillus salivarius for the treatment of mastitis
AU2018225957A1 (en) Composition for alleviating mental health disorder
PH12018550110A1 (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
CL2017001818A1 (es) Bacteria de ácido láctico y su uso para el tratamiento de mastitis
MX2019006086A (es) Uso de una composicion bacteriana para tratar infecciones en las patas de ungulados.
RU2010150205A (ru) Лечебно-профилактический препарат на основе антималярийного средства и пробиотика
HK1210173A1 (en) Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators
MX2020001501A (es) Streptococcus australis como bioterapeuticos.